<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJU</journal-id><journal-title-group><journal-title>Open Journal of Urology</journal-title></journal-title-group><issn pub-type="epub">2160-5440</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oju.2016.65016</article-id><article-id pub-id-type="publisher-id">OJU-66630</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Clear Discrepancy in Neurofibromin Expression between NF1 Pheochromocytoma Cells and Non-Tumorous Adrenal Medullary Cells
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>oji</surname><given-names>Mikami</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yumiko</surname><given-names>Okuno</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Masayoshi</surname><given-names>Zaitsu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hiroki</surname><given-names>Tanaka</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Koichi</surname><given-names>Sakazume</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Akiko</surname><given-names>Tonooka</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Toshimasa</surname><given-names>Uekusa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takumi</surname><given-names>Takeuchi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Pathology, Kanto Rosai Hospital, Kawasaki, Japan</addr-line></aff><aff id="aff1"><addr-line>Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>takeuchit@abelia.ocn.ne.jp(TT)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>05</month><year>2016</year></pub-date><volume>06</volume><issue>05</issue><fpage>86</fpage><lpage>90</lpage><history><date date-type="received"><day>15</day>	<month>March</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>17</month>	<year>May</year>	</date><date date-type="accepted"><day>20</day>	<month>May</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Neurofibromatosis type 1 (NF1) is a common inherited disorder with an autosomal dominant trait. We encountered an NF1 patient who showed adrenal pheochromocytoma, and analyzed expression of neurofibromin in an excised specimen. A 54-year-old man showing multiple neurofibromas and caf&#233;-au-lait spots in the skin was pointed out to have a right adrenal tumor by ultrasonography. Abdominal CT also revealed a right adrenal tumor. He was diagnosed with neurofibromatosis type 1 with no family history. Urine catecholamines, metanephrine, and normetanephrine levels were elevated. MIBG scintigraphy showed positive right adrenal uptake, and so pheochromocytoma was also diagnosed. The patient underwent laparoscopic right adrenalectomy. The excised adrenal specimen of this patient was stained with anti-neurofibromin polyclonal antibody. The NF1 pheochromocytoma was completely negative for neurofibromin protein expression, while the NF1 non-pheochromocytomatous adrenal medulla was neurofibromin-positive in the cytoplasm and nucleus. The clear discrepancy in neurofibromin expression between pheochromocytoma cells and “normal” adrenal medullary cells of the patient may well be explained by Knudson’s two-hit hypothesis.
 
</p></abstract><kwd-group><kwd>Pheochromocytoma</kwd><kwd> NF1</kwd><kwd> Neurofibromin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Neurofibromatosis type 1 (NF1) is a common inherited disorder with an autosomal dominant trait caused by mutations of the NF1 gene of 360kb and 73 exons located at chromosome 17q11.2. The incidence rate of NF1 is about 1 in 3500 [<xref ref-type="bibr" rid="scirp.66630-ref1">1</xref>] . The diagnosis of NF1 is based on clinical assessment and requires two or more of the following features: (a) 6 or more caf&#233;-au-lait macules, (b) 2 or more cutaneous/subcutaneous neurofibromas or one plexiform neurofibroma, (c) axillary or groin freckling, (d) optic pathway glioma, (e) 2 or more Lisch nodules (iris hamartomas), (f) bony dysplasia, (g) first degree relative with NF1 [<xref ref-type="bibr" rid="scirp.66630-ref2">2</xref>] . NF1 also shows learning deficits and predisposition to the formation of various types of benign/malignant tumors including pheochromocytoma [<xref ref-type="bibr" rid="scirp.66630-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.66630-ref5">5</xref>] .</p><p>Neurofibromin, the product of the NF1 gene of 2818 amino acids, is a Ras-GTPase-activating protein, negatively regulates the Ras/MAPK, PI3K, and mTOR signaling pathways [<xref ref-type="bibr" rid="scirp.66630-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.66630-ref7">7</xref>] , and functions as a tumor suppressor protein. Here, we encountered an NF1 patient who showed pheochromocytoma and analyzed the expression of neurofibromin in an excised adrenal specimen.</p></sec><sec id="s2"><title>2. Case Report</title><p>A 54-year-old man was pointed out to have a right adrenal tumor on ultrasonography during ordinary health screening and was referred to the Department of Endocrinology of Kanto Rosai Hospital. His height was 170 cm and his weight was 63 kg. His systolic/diastolic blood pressures on admission were 146/86 mmHg with the administration of anti-hypertensive drugs, heart rate 78 beats per minute, saturation 98% on room air. The electrocardiogram showed left ventricular hypertrophy. The man showed multiple neurofibromas and caf&#233;-au-lait spots in the skin (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and Lisch nodules were ophthalmologically found. So, he was also diagnosed with neurofibromatosis type 1 with no family history. He had no skeletal abnormalities or learning deficits.</p><p>Abdominal CT also revealed a right adrenal tumor of 3.0 cm in diameter (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Urine catecholamines, metanephrine, and normetanephrine levels were elevated, as shown in <xref ref-type="table" rid="table1">Table 1</xref>. MIBG scintigraphy showed positive right adrenal uptake (<xref ref-type="fig" rid="fig3">Figure 3</xref>), and so pheochromocytoma was diagnosed.</p><fig-group id="fig1"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Skin lesions, neurofibromas and a caf&#233;-au-lait spot.</title></caption><fig id ="fig1_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/3-5000334x7.png"/></fig></fig-group><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> An abdominal CT scan. The yellow arrow indicates a right adrenal tumor</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/3-5000334x8.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Urine catecholamines, metanephrine, and normetanephrine levels before right adrenalectomy</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Adrenalin</th><th align="center" valign="middle" >58.9 μg/day</th><th align="center" valign="middle" >(3.4 - 26.9)</th></tr></thead><tr><td align="center" valign="middle" >Noradrenalin</td><td align="center" valign="middle" >457.9 μg/day</td><td align="center" valign="middle" >(48.6 - 168.5)</td></tr><tr><td align="center" valign="middle" >Dopamine</td><td align="center" valign="middle" >2786.2 μg/day</td><td align="center" valign="middle" >(365.0 - 961.5)</td></tr><tr><td align="center" valign="middle" >Metanephrine</td><td align="center" valign="middle" >0.55 mg/day</td><td align="center" valign="middle" >(0.04 - 0.19)</td></tr><tr><td align="center" valign="middle" >Normetanephrine</td><td align="center" valign="middle" >0.94 mg/day</td><td align="center" valign="middle" >(0.09 - 0.33)</td></tr></tbody></table></table-wrap><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> MIBG scintigraphy indicating positive right adrenal uptake</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/3-5000334x9.png"/></fig><p>The patient underwent laparoscopic right adrenalectomy under general anesthesia. During mobilization of the tumor, the systolic blood pressure elevated to as high as 200 mmHg, then it dropped to around 80 mmHg following ligation of the right adrenal veins. The post-operative course was uneventful. The pathology was pheochromocytoma with positive staining of chromogranin A (<xref ref-type="fig" rid="fig4">Figure 4</xref>) and histological characteristics implying malignant potential were not observed. One year after right adrenalectomy, there was no recurrence of pheochromocytoma and his systolic/diastolic blood pressures were 120/74 mmHg.</p></sec><sec id="s3"><title>3. Immunohistochemistry of Neurofibromin</title><p>An excised adrenal specimen of this patient as well as a sporadic pheochromocytoma was stained with anti- neurofibromin polyclonal antibody (ab30325, Abcam, Cambridge, UK). As shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>, the NF1 pheo- chromocytoma was completely negative for neurofibromin protein expression, while the non-pheochromocyto- matous adrenal medulla was neurofibromin-positive in the cytoplasm and nucleus. Sporadic pheochromocytoma of a non-NF1 patient was positively stained for neurofibromin in the cytoplasm and nucleus.</p></sec><sec id="s4"><title>4. Discussion</title><p>Sporadic NF1 cases without a family history comprise 30% - 50% among all NF1 patients, and the significance of advanced paternal age has been indicated [<xref ref-type="bibr" rid="scirp.66630-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.66630-ref9">9</xref>] . Those cases are caused by a novel mutation in the NF1 gene in the germ cell of either parent. According to Knudson’s two-hit hypothesis of hereditary tumors, a germline mutation in a tumor suppressor gene in one allele is inherited and another mutation in the other allele is generated in somatic cells by the second hit. The second hit is not rare, and so the cancer susceptibility is actually inherited dominantly [<xref ref-type="bibr" rid="scirp.66630-ref10">10</xref>] . Following this two-hit theory, pheochromocytoma cells in this case must have NF1 mutations in both alleles, while “normal” adrenal medullar cells of the patient theoretically have NF1 mutation in one allele only. A clear discrepancy in neurofibromin staining between pheochromocytoma cells and “normal” adrenal medullary cells may well be explained by the two-hit hypothesis in the present case.</p><fig id="fig4"  position="float"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> Hematoxylin &amp; Eosin staining (left) and immunohistochemistry of neurofibromin (middle)/ chromogranin A (right). Upper: an NF1 pheochromocytoma, Lower: a sporadic non-NF1 pheochromocytoma. N: non-pheochromatous adrenal medulla, P: pheochromocytoma. The border of the non- pheochromatous NF1 adrenal medulla and NF1 pheochromocytoma is magnified at the corner</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/3-5000334x10.png"/></fig><p>Pheochromocytomas were clinically identified in 5.7% of NF1 patients, while 9.6% of those tumors was bilateral, 6.1% was extra-adrenal, and 11.5% was malignant [<xref ref-type="bibr" rid="scirp.66630-ref11">11</xref>] . The present case was a solitary, unilateral, adrenal, and benign pheochromocytoma with a common clinical manifestation. However, there are not preceding reports that clearly differentiate histological neurofibromin expression between an NF1 pheochromocytoma and its surrounding non-tumorous adrenal medulla, strongly supporting Knudson’s two-hit hypothesis.</p><p>Gutmann et al. reported that seven NF1 pheochromocytoma tissues did not express neurofibromin protein at all based on Western blotting [<xref ref-type="bibr" rid="scirp.66630-ref12">12</xref>] , while Kimura et al. showed that an NF1 pheochromocytoma expressed NF1 mRNA and neurofibromin protein assessed by restriction enzyme digestion of PCR products and immunohistochemistry, respectively [<xref ref-type="bibr" rid="scirp.66630-ref13">13</xref>] . The latter NF1 case may have mutations in NF1 genes of both alleles, either of which is transcribed and translated into aberrant neurofibromin protein without its full function. Nf +/− mice heterozygous for human NF1 homologue mutation are highly susceptible to the formation of various types of tumor, notably pheochromocytomas. Nf1−/− mice were mid-embryonic lethal due to abnormal cardiac development [<xref ref-type="bibr" rid="scirp.66630-ref14">14</xref>] .</p><p>Hereditary pheochromocytomas are also observed in von Hippel-Lindau disease (VHL gene), multiple endocrine neoplasia type 2 (RET gene), and pheochromocytoma/paraganglioma syndrome (SDHx genes) in addition to NF1 [<xref ref-type="bibr" rid="scirp.66630-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.66630-ref5">5</xref>] . Moreover, 23.8% of sporadic pheochromocytomas exhibited somatic NF1 mutations [<xref ref-type="bibr" rid="scirp.66630-ref15">15</xref>] . The sporadic non-NF1 pheochromocytoma shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> may not have NF1 mutations in either allele, as neurofibromin protein was expressed in pheochromocytoma cells.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In conclusion, here we presented a case of NF1 pheochromocytoma in which neurofibromin protein expression was clearly distinct between pheochromocytoma cells and non-pheochromocytomatous adrenal medullary cells, supporting Knudson’s two-hit hypothesis.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We thank Junzo Tomoishi, who passed away in 2015, for his scientific contribution to this article.</p></sec><sec id="s7"><title>Disclosure</title><p>The authors declare that there is no conflict of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Koji Mikami,Yumiko Okuno,Masayoshi Zaitsu,Hiroki Tanaka,Koichi Sakazume,Akiko Tonooka,Toshimasa Uekusa,Takumi Takeuchi, (2016) Clear Discrepancy in Neurofibromin Expression between NF1 Pheochromocytoma Cells and Non-Tumorous Adrenal Medullary Cells. Open Journal of Urology,06,86-90. doi: 10.4236/oju.2016.65016</p></sec><sec id="s9"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.66630-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Theos, A. and Korf, B.R. (2006) Pathophysiology of Neurofibromatosis Type 1. Annals of Internal Medicine, 144, 842-849. http://dx.doi.org/10.7326/0003-4819-144-11-200606060-00010</mixed-citation></ref><ref id="scirp.66630-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">(1988) National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. Archives of Neurology, 45, 575-578.</mixed-citation></ref><ref id="scirp.66630-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Laycock-van Spyk, S., Thomas, N., Cooper, D.N. and Upadhyaya, M. (2011) Neurofibromatosis Type 1-Associated Tumours: Their Somatic Mutational Spectrum and Pathogenesis. Human Genomics, 5, 623-690. http://dx.doi.org/10.1186/1479-7364-5-6-623</mixed-citation></ref><ref id="scirp.66630-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kolackov, K., Tupikowski, K. and Bednarek-Tupikowska, G. (2012) Genetic Aspects of Pheochromocytoma. Advances in Clinical and Experimental Medicine, 21, 821-829.</mixed-citation></ref><ref id="scirp.66630-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Welander, J., Soderkvist, P. and Gimm, O. (2013) The NF1 Gene: A Frequent Mutational Target in Sporadic Pheochromocytomas and Beyond. Endocrine-Related Cancer, 20, C13-C17. http://dx.doi.org/10.1530/ERC-13-0046</mixed-citation></ref><ref id="scirp.66630-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Harrisingh, M.C. and Lloyd, A.C. (2004) Ras/Raf/ERK Signalling and NF1. Cell Cycle, 3, 1255-1258. http://dx.doi.org/10.4161/cc.3.10.1182</mixed-citation></ref><ref id="scirp.66630-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Le, L.Q. and Parada, L.F. (2007) Tumor Microenvironment and Neurofibromatosis Type I: Connecting the GAPs. Oncogene, 26, 4609-4616. http://dx.doi.org/10.1038/sj.onc.1210261</mixed-citation></ref><ref id="scirp.66630-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Snajderova, M., Riccardi, V.M., Petrak, B., Zemkova, D., Zapletalova, J., Mardesic, T., Petrakova, A., Lanska, V., Marikova, T., Bendova, S., Havlovicova, M. and Kaluzova, M. (2012) The Importance of Advanced Parental Age in the Origin of Neurofibromatosis Type 1. American Journal of Medical Genetics Part A, 158A, 519-523. http://dx.doi.org/10.1002/ajmg.a.34413</mixed-citation></ref><ref id="scirp.66630-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bunin, G.R., Needle, M. and Riccardi, V.M. (1997) Paternal Age and Sporadic Neurofibromatosis 1: A Case-Control Study and Consideration of the Methodological Issues. Genetic Epidemiology, 14, 507-516. http://dx.doi.org/10.1002/(SICI)1098-2272(1997)14:5&lt;507::AID-GEPI5&gt;3.0.CO;2-Y</mixed-citation></ref><ref id="scirp.66630-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Berger, A.H., Knudson, A.G. and Pandolfi, P.P. (2011) A Continuum Model for Tumour Suppression. Nature, 476, 163-169. http://dx.doi.org/10.1038/nature10275</mixed-citation></ref><ref id="scirp.66630-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Walther, M.M., Herring, J., Enquist, E., Keiser, H.R. and Linehan, W.M. (1999) von Recklinghausen’s Disease and Pheochromocytomas. The Journal of Urology, 162, 1582-1586. http://dx.doi.org/10.1016/S0022-5347(05)68171-2</mixed-citation></ref><ref id="scirp.66630-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Gutmann, D.H., Cole, J.L., Stone, W.J., Ponder, B.A. and Collins, F.S. (1994) Loss of Neurofibromin in Adrenal Gland Tumors from Patients with Neurofibromatosis Type 1. Genes, Chromosomes and Cancer, 10, 55-58. http://dx.doi.org/10.1002/gcc.2870100109</mixed-citation></ref><ref id="scirp.66630-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kimura, N., Watanabe, T., Fukase, M., Wakita, A., Noshiro, T. and Kimura, I. (2002) Neurofibromin and NF1 Gene Analysis in Composite Pheochromocytoma and Tumors Associated with von Recklinghausen’s Disease. Modern Pathology, 15, 183-188. http://dx.doi.org/10.1038/modpathol.3880513</mixed-citation></ref><ref id="scirp.66630-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jacks, T., Shih, T.S., Schmitt, E.M., Bronson, R.T., Bernards, A. and Weinberg, R.A. (1994) Tumor Predisposition in Mice Heterozygous for a Targeted Mutation in NF1. Nature Genetics, 7, 353-361. http://dx.doi.org/10.1038/ng0794-353</mixed-citation></ref><ref id="scirp.66630-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Welander, J., Larsson, C., Backdahl, M., Hareni, N., Sivler, T., Brauckhoff, M., Soderkvist, P. and Gimm, O. (2012) Integrative Genomics Reveals Frequent Somatic NF1 Mutations in Sporadic Pheochromocytomas. Human Molecular Genetics, 21, 5406-5416. http://dx.doi.org/10.1093/hmg/dds402</mixed-citation></ref></ref-list></back></article>